Gossamer Bio, Inc. GOSS
9.28 USD -0.17 (-1.80%)
At closeNov 3, 2026, 4:27 PM EST
9.20 -0.08 -0.86%
After hours · Nov 3, 4:27 PM ET
8.80 Day range 9.68
8.29 52-week range 309.60
- YTD
- -96.26%
- 1 year
- -95.15%
Analyst view
Price target (mean) 132.48 +1327.6% upside
Now 9.28
- Target (low)
- 22.40
- Target (mean)
- 132.48
- Target (high)
- 320.00
Ratings (0m) 7 3 buy · 3 hold · 1 sell
- Strong buy1
- Buy2
- Hold3
- Sell0
- Strong sell1
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -3.89 | -7.20 – 0.80 | -16.80 | +76.9% | 10.67M | -19.7% | 5 |
| Next quarter | -4.96 | -6.40 – -3.20 | -16.80 | +70.5% | 0 | -100.0% | 5 |
| Current year | -14.40 | -17.60 – -11.20 | -60.00 | +76.0% | 35.86M | -26.0% | 2 |
| Next year | -15.62 | -28.80 – -2.88 | -14.40 | -8.4% | 20.00M | -44.2% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Jul 28, 2026 | Leerink Partners | Upgrade | Market Perform | Outperform |
| Jul 27, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 25, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 26, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 19, 2026 | Barclays | Maintained | Underweight | Underweight |
| Mar 23, 2026 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Mar 6, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 5, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 24, 2026 | Wedbush | Downgrade | Outperform | Neutral |
| Feb 24, 2026 | Barclays | Downgrade | Overweight | Underweight |
| Feb 24, 2026 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Jan 28, 2026 | Barclays | Initiated | — | Overweight |
| Jan 22, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 11, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 10, 2025 | UBS | Upgrade | Neutral | Buy |
| Aug 6, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Jul 14, 2025 | Scotiabank | Initiated | — | Sector Outperform |
| May 16, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| May 16, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Apr 17, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Mar 14, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Jan 30, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 11, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 17, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 30, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 13, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 25, 2024 | Oppenheimer | Initiated | — | Outperform |
| Jun 17, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| May 20, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |